

**POST-TRANSPLANT RECORD (6-12 months)**

Patient's Name: \_\_\_\_\_ SLCBBB ID: \_\_\_\_\_  
 Transplant Center: \_\_\_\_\_ Transplant Physician: \_\_\_\_\_  
 F/U Physician: \_\_\_\_\_ Medical Center: \_\_\_\_\_

**1. Patient's current status:**

**Alive**  yes  No

Date of Death: \_\_\_\_\_ Autopsy  yes  no  
Month-day-year

Cause of Death: \_\_\_\_\_

**Relapse or Recurrence Of Disease**  yes  no Date: \_\_\_\_\_  
Month-day-year

**2. Engraftment/Hematologic evaluation** (most recent) date: \_\_\_\_\_  
Month-day-year

**a) CBC**  
 WBC: \_\_\_\_\_ ANC: \_\_\_\_\_ Plts: \_\_\_\_\_ Hct/Hb: \_\_\_\_\_

ABO Type: \_\_\_\_\_ Rh: \_\_\_\_\_  
 Plts > 20,000/ $\mu$  L  yes  no Date: \_\_\_\_\_  
 Plts > 50,00/ $\mu$  L  yes  no Date: \_\_\_\_\_

**b) Transfusions**  yes  no  
 Platelets  yes  no If no, date of last transfusion: \_\_\_\_\_  
 PRBCs  yes  no If no, date of last transfusion: \_\_\_\_\_

**c) Chimerism studies performed at your Center**  Yes  No  
**Most recent,** Date: \_\_\_\_\_ **Method:** \_\_\_\_\_  
**Peripheral blood** \_\_\_\_\_ % donor **Bone marrow** \_\_\_\_\_ % donor

**d) Secondary Graft Failure**  Yes  No Date: \_\_\_\_\_

**e) New or persistent hematologic problems**  Yes  No  
 If yes, describe: \_\_\_\_\_  
 Suspected etiology? \_\_\_\_\_

**f) Need for temporary growth factor support**  Yes  No  
 Agent: \_\_\_\_\_ Date started: \_\_\_\_\_ Date stopped: \_\_\_\_\_

**g) Did the patient receive other stem cell transplant after the STLCBB's Unit?**  
 yes  No **If yes,** date: \_\_\_\_\_  
Month-day-year

**If yes, type:**  Autologous BM  Autologous PBSC  
 Related BM  Related PBSC  
 Unrelated BM  Unrelated PBSC  
 Related PCB  Unrelated PCB unit  
 (BM: bone marrow, PBSC: peripheral blood stem cells, PCB: placental/cord blood)

**If yes, reason:** \_\_\_\_\_

**3. Immune reconstitution**  complete  partial  
 Immunoglobulin levels  Normal  Low Date: \_\_\_\_\_  
 PhA stimulation  Normal  Decreased Date: \_\_\_\_\_  
 NK cells  Normal  Decreased Date: \_\_\_\_\_  
 T-cells/subsets  Normal  Decreased Date: \_\_\_\_\_  
 B-cells/subsets  Normal  Decreased Date: \_\_\_\_\_

Other: \_\_\_\_\_ Date: \_\_\_\_\_

**Immunizations re-instituted:**  yes  no Date: \_\_\_\_\_

**4. Chronic GvHD:**

- a) **Evidence of chronic GvHD:**  Yes  No Date of dx: \_\_\_\_\_  
Site:  Skin  Limited  extensive  
 Gut  
 Liver

Other organ involvement: \_\_\_\_\_

Biopsy for GvHD  Yes  No Site: \_\_\_\_\_  
Pathology consistent with GvHD  yes  no

**GvHD treatment**

Agent: \_\_\_\_\_ Date started: \_\_\_\_\_ Date stopped: \_\_\_\_\_

Agent: \_\_\_\_\_ Date started: \_\_\_\_\_ Date stopped: \_\_\_\_\_

**Response**  None  Improved  Resolved

**5. Infections (6-12 months after transplant)**

- a) **Bacterial** Site: \_\_\_\_\_ Organism: \_\_\_\_\_ Date of dx: \_\_\_\_\_  
Site: \_\_\_\_\_ Organism: \_\_\_\_\_ Date of dx: \_\_\_\_\_  
Site: \_\_\_\_\_ Organism: \_\_\_\_\_ Date of dx: \_\_\_\_\_
- b) **Viral** Site: \_\_\_\_\_ Organism: \_\_\_\_\_ Date of dx: \_\_\_\_\_  
Site: \_\_\_\_\_ Organism: \_\_\_\_\_ Date of dx: \_\_\_\_\_  
Site: \_\_\_\_\_ Organism: \_\_\_\_\_ Date of dx: \_\_\_\_\_
- c) **Fungal** Site: \_\_\_\_\_ Organism: \_\_\_\_\_ Date of dx: \_\_\_\_\_  
Site: \_\_\_\_\_ Organism: \_\_\_\_\_ Date of dx: \_\_\_\_\_  
Site: \_\_\_\_\_ Organism: \_\_\_\_\_ Date of dx: \_\_\_\_\_
- d) **Parasitic:** Site: \_\_\_\_\_ Organism: \_\_\_\_\_ Date of dx: \_\_\_\_\_

**6. Non-Infectious complications (6-12 months after transplant):**

- a) **Pulmonary**  Yes  No  
 Interstitial pneumonia  Bronchiolitis obliterans  
 Restrictive airway disease  Pulmonary edema  
 Obstructive airway disease  Other: \_\_\_\_\_
- b) **Cardiac**  Yes  No  
 Cardiomyopathy  
 Congestive heart failure  Other: \_\_\_\_\_
- c) **Renal**  Yes  No  
 Nephritis  
 Renal failure  Other: \_\_\_\_\_
- d) **GI**  Yes  No  
 Liver Dysfunction  Other: \_\_\_\_\_
- f) **Endocrine**  Yes  No  
 Thyroid  Adrenal  
 Gonadal  Other: \_\_\_\_\_  
 Pituitary Describe: \_\_\_\_\_

Patient's Name: \_\_\_\_\_ SLCBB ID: \_\_\_\_\_

**7. Other treatments/prophylaxis**

PCP prophylaxis	<input type="checkbox"/>	Yes	<input type="checkbox"/>	No	Agent: _____	Duration of tx: _____
Fungal prophylaxis	<input type="checkbox"/>	Yes	<input type="checkbox"/>	No	Agent: _____	Duration of tx: _____
Antiviral agents	<input type="checkbox"/>	Yes	<input type="checkbox"/>	No	Agent: _____	Duration of tx: _____
IVIG	<input type="checkbox"/>	Yes	<input type="checkbox"/>	No	Frequency of Tx: _____	

Other: \_\_\_\_\_

**8. Development of other disease or second malignancy:**

no  no Specify: \_\_\_\_\_

**9. Evaluation of primary disease (other than malignancy)**

\_\_\_\_\_  
\_\_\_\_\_

**10. Additional Comments:**

\_\_\_\_\_  
\_\_\_\_\_

**Form completed by:**

\_\_\_\_\_ (print) Date: \_\_\_\_\_  
month-day-year

\_\_\_\_\_ (signature) Tel: \_\_\_\_\_

Fax: \_\_\_\_\_